Stockscreener 앱 받기
1.56
4.88%
-0.08
시간 외 거래:
1.61
0.05
+3.21%
Mindwalk Holdings Corp 주식(HYFT)의 최신 뉴스
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery - 01net
MindWalk CEO to Join Jones AI Day Panel on Future of AI Drug Discovery - TipRanks
MindWalk (NASDAQ: HYFT) CEO joins Jones AI Day panel on AI drug discovery - Stock Titan
HYFT Unveils ReefIQ for Enhanced AI Drug Discovery - GuruFocus
MindWalk Holdings Corp. Launches ReefIQ™ for AI-Driven Drug Disc - GuruFocus
MindWalk Holdings Unveils ReefIQ Context Layer to Power AI Drug Discovery - TipRanks
[6-K] MindWalk Holdings Corp. Current Report (Foreign Issuer) | HYFT SEC FilingForm 6-K - Stock Titan
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery - The Joplin Globe
HYFT Q1 2026 Earnings: EPS Falls Short of Estimates as Stock Gains 3.75%EPS Growth Report - newsline.com
Top MindWalk (HYFT) Competitors 2026 - MarketBeat
HYFT Q1 2026 Earnings: EPS Misses Estimates, Stock Slides Over 9%Earnings Power Value - newsline.com
MindWalk (HYFT) Earnings Date and Reports 2026 - MarketBeat
MindWalk Showcases HYFT® Platform With Pan-Serotype Dengue Preclinical Data - TipRanks
MindWalk (NASDAQ: HYFT) reports HYFT AI preclinical dengue antibodies across all four serotypes - Stock Titan
MindWalk's HYFT Platform Shows Promising Preclinical Dengue Vacc - GuruFocus
MindWalk reports preclinical dengue vaccine data By Investing.com - Investing.com Nigeria
Bio-Native AI therapeutics MindWalk sets March 12 Q3 earnings call - Stock Titan
MindWalk reports preclinical dengue vaccine data - Investing.com
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Camp - Business Wire
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6%, Stock DeclinesOne-Time Gain Impact - thelegaladvocate.com
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6%, Stock Declines 1.68%Share Dilution Risk - newsline.com
HYFT Q1 2026 Earnings: EPS Misses Estimates by 42.6% as Losses WidenGrowth Acceleration Report - The Legal Advocate
HYFT Q1 2026 Earnings: EPS Misses Estimates by a Wide 42.6% MarginProfit Inflection Point - newsline.com
MindWalk Stock Slips as AI Pandemic Platform Launch Puts HYFT Back in Focus - Bez Kabli
MindWalk Holdings Corp. (HYFT) Climbs 4.68%, Testing Key Resistance at $1.88Hot Stock Picks - The Legal Advocate
MindWalk (HYFT) Introduces Innovative Pandemic Response Platform - GuruFocus
MindWalk Holdings (HYFT) Climbs 4.91% as Buying Interest Builds Near Key SupportFast Moving Stocks - The Legal Advocate
MindWalk Company Profile & Introduction - Moomoo
MindWalk Holdings déploie une plateforme de réponse aux pandémies via la technologie HYFT® alors que les épidémies d'Ebola et d'hantavirus révèlent les limites de la couverture spécifique à chaque souche - Weekly Voice
MindWalk Holdings Corp. (HYFT) Launches Pandemic Response Platfo - GuruFocus
MindWalk Holdings Corp. (HYFT) Launches Pandemic Response Platform for Broad Protection - GuruFocus
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage - 01net
MindWalk Holdings Launches AI-Driven Pandemic Response Platform for RNA Virus Outbreaks - TipRanks
MindWalk Holdings (NASDAQ: HYFT) unveils AI pandemic response platform for RNA viruses - Stock Titan
MindWalk Holdings Corp. (HYFT) Faces Selling Pressure as Price Approaches Key Support ZoneValue ETF - The Legal Advocate
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
MindWalk’s Rebrand Turned A CRO Into An AI Platform Story - Finimize
MindWalk Holdings Corp.Common Stock (Nasdaq:HYFT) Stock Quote - The Chronicle-Journal
H.C. Wainwright reiterates MindWalk stock rating on platform validation - Investing.com
H.C. Wainwright reiterates MindWalk stock rating on platform validation By Investing.com - Investing.com Canada
HYFT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
MindWalk (HYFT) Reports on Drug Candidates from Antibody Discove - GuruFocus
MindWalk Highlights 20-Plus Partner Drug Programs Tied to Its Discovery Platform - TipRanks
The Biology Came First. - Investing News Network
1.04%
0.76%
자본화:
|
볼륨(24시간):